Updates in chronic obstructive pulmonary disease (COPD)

Published on December 31, 2017   42 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

Other Talks in the Series: Advances in Chronic Obstructive Pulmonary Disease (COPD)

Hello. I'm Omar Usmani. I'm a Reader in Respiratory Medicine at Imperial College London and a Consultant Physician at the Royal Brompton Hospital. I'm going to be talking about updates in Chronic Obstructive Pulmonary Disease, COPD, particularly those in the last two years that have had an influence on our clinical practice and may also help us guide research in the future years.
And this is my faculty disclosure and I wanted to emphasize that I have no shares in any of the company and I have no relationship of any kind with the tobacco industry.
So, I will review the anatomy and the pathology, and how that relates to the physiology and importantly, how that determines our management and treatment and pharmacological approach of patients with COPD in the clinic.
So, I will review five key areas: clinical characteristics, the Pathophysiology of patients with COPD, how we're assessing the lungs and novel methods of assessing the lungs that have appeared over the last few years, the new disease classifications we have seen particularly this year, and also, how that reflects on our new approach to the therapeutic management of patients with COPD.
So, this year, we have seen the Global Initiative of Obstructive Lung Disease or GOLD update their document. And there are five key points related to COPD. The first that we are aware of is that COPD is a preventable and treatable disease that is characterized by persistent respiratory symptoms. Importantly, is point two, and that the symptoms of dyspnea, cough, and sputum production may actually be under-reported, and a key point for us to reflect on this is our ability to assess patients with COPD and find these patients, not just in secondary care, but also primary care and using Spirometry in an effective manner to find these patients. The third point we see is that certainly tobacco smoking is an important risk factor for COPD, but a lot of research over the last few years has shown that biomass fuel exposure and air pollution certainly may contribute to the manifestation of patients with COPD. We also need to realize that COPD can be punctuated by periods of acute worsening of respiratory symptoms called exacerbations and we will pick up on this a little bit later.

Updates in chronic obstructive pulmonary disease (COPD)

Embed in course/own notes